Critical role of endoplasmic reticulum aminopeptidase 1 in determining the length and sequence of peptides bound and presented by HLA-B27
Critical role of endoplasmic reticulum aminopeptidase 1 in determining the length and sequence of peptides bound and presented by HLA-B27
Objective
HLA–B27 and endoplasmic reticulum aminopeptidase 1 (ERAP1) are the two strongest genetic factors predisposing to ankylosing spondylitis (AS). A key aminopeptidase in class I major histocompatibility complex presentation, ERAP1 potentially contributes to the pathogenesis of AS by altering HLA–B27 peptide presentation. The aim of this study was to analyze the effects of ERAP1 on the HLA–B27 peptide repertoire and peptide presentation to cytotoxic T lymphocytes (CTLs).
Methods
ERAP1-silenced and -competent HeLa.B27 and C1R.B27 cells were isotope-labeled, mixed, lysed, and then immunoprecipitated using W6/32 or ME1 antibodies. Peptides bound to HLA–B27 were eluted and analyzed by tandem mass spectrometry. Selected peptides were synthesized and tested for HLA–B27 binding ability. The effect of ERAP1 silencing/mutation on presentation of an immunodominant viral HLA–B27 epitope, KK10, to CTLs was also studied.
Results
In both HeLa.B27 and C1R.B27 cells, the proportion of 9-mer HLA–B27–bound peptides was decreased by ERAP1 silencing, whereas the percentages of longer peptides (11–13 mer) were increased. Surprisingly, following ERAP1 silencing, C-terminally extended peptides were readily identified. These were better able to bind to HLA–B27 than were N-terminally extended peptides lacking an arginine at position 2. In both HeLa.B27 cells and mouse fibroblasts expressing HLA–B27, the absence of ERAP1 reduced peptide recognition by HLA–B27–restricted KK10-specific CTLs following infection with recombinant vaccinia virus or transfection with minigenes expressing KK10 precursors. Presence of an AS-protective variant of ERAP1, K528R, as compared to wild-type ERAP1, reduced the peptide recognition by KK10 CTLs following transfection with extended KK10 minigenes.
Conclusion
These results show that ERAP1 directly alters peptide binding and presentation by HLA–B27, thus demonstrating a potential pathogenic mechanism in AS. Inhibition of ERAP1 could potentially be used for treatment of AS and other ERAP1-associated diseases.
284-294
Chen, Liye
0d13d425-436a-446c-8483-0206fed7f2b2
Fischer, Roman
e95c6d9b-b9c5-43a9-9529-a6cd50ddba0c
Peng, Yanchun
73557cbd-83f0-4cca-beed-04eb099b3ed1
Reeves, Emma
bd61ff0c-6555-47fd-884f-74dc6105e846
McHugh, Kirsty
62c0af77-c8b1-4d57-986e-7793f83828db
Ternette, Nicola
4086d520-7d90-47fb-a42a-987aa1038911
Hanke, Tomas
8b2d9730-f490-4a67-bfe9-c9e867a6979c
Dong, Tao
942142fb-76a5-430c-85ae-17155db4263d
Elliott, Tim
16670fa8-c2f9-477a-91df-7c9e5b453e0e
Shastri, Nilabh
8af29105-c59b-4260-bdde-a97c016e0793
Kollnberger, Simon
1eebc521-8d86-4db3-98d6-25a6e9e2fdf0
James, Edward
7dc1afb7-d326-4050-89fc-1f4e2a1a19a4
Kessler, Benedikt
6dd4895f-85fb-4538-87eb-69cf1dda7c70
Bowness, Paul
b8c5ab84-2528-4cd2-b44e-f1eb3a45baa9
February 2014
Chen, Liye
0d13d425-436a-446c-8483-0206fed7f2b2
Fischer, Roman
e95c6d9b-b9c5-43a9-9529-a6cd50ddba0c
Peng, Yanchun
73557cbd-83f0-4cca-beed-04eb099b3ed1
Reeves, Emma
bd61ff0c-6555-47fd-884f-74dc6105e846
McHugh, Kirsty
62c0af77-c8b1-4d57-986e-7793f83828db
Ternette, Nicola
4086d520-7d90-47fb-a42a-987aa1038911
Hanke, Tomas
8b2d9730-f490-4a67-bfe9-c9e867a6979c
Dong, Tao
942142fb-76a5-430c-85ae-17155db4263d
Elliott, Tim
16670fa8-c2f9-477a-91df-7c9e5b453e0e
Shastri, Nilabh
8af29105-c59b-4260-bdde-a97c016e0793
Kollnberger, Simon
1eebc521-8d86-4db3-98d6-25a6e9e2fdf0
James, Edward
7dc1afb7-d326-4050-89fc-1f4e2a1a19a4
Kessler, Benedikt
6dd4895f-85fb-4538-87eb-69cf1dda7c70
Bowness, Paul
b8c5ab84-2528-4cd2-b44e-f1eb3a45baa9
Chen, Liye, Fischer, Roman, Peng, Yanchun, Reeves, Emma, McHugh, Kirsty, Ternette, Nicola, Hanke, Tomas, Dong, Tao, Elliott, Tim, Shastri, Nilabh, Kollnberger, Simon, James, Edward, Kessler, Benedikt and Bowness, Paul
(2014)
Critical role of endoplasmic reticulum aminopeptidase 1 in determining the length and sequence of peptides bound and presented by HLA-B27.
Arthritis & Rheumatology, 66 (2), .
(doi:10.1002/art.38249).
(PMID:24504800)
Abstract
Objective
HLA–B27 and endoplasmic reticulum aminopeptidase 1 (ERAP1) are the two strongest genetic factors predisposing to ankylosing spondylitis (AS). A key aminopeptidase in class I major histocompatibility complex presentation, ERAP1 potentially contributes to the pathogenesis of AS by altering HLA–B27 peptide presentation. The aim of this study was to analyze the effects of ERAP1 on the HLA–B27 peptide repertoire and peptide presentation to cytotoxic T lymphocytes (CTLs).
Methods
ERAP1-silenced and -competent HeLa.B27 and C1R.B27 cells were isotope-labeled, mixed, lysed, and then immunoprecipitated using W6/32 or ME1 antibodies. Peptides bound to HLA–B27 were eluted and analyzed by tandem mass spectrometry. Selected peptides were synthesized and tested for HLA–B27 binding ability. The effect of ERAP1 silencing/mutation on presentation of an immunodominant viral HLA–B27 epitope, KK10, to CTLs was also studied.
Results
In both HeLa.B27 and C1R.B27 cells, the proportion of 9-mer HLA–B27–bound peptides was decreased by ERAP1 silencing, whereas the percentages of longer peptides (11–13 mer) were increased. Surprisingly, following ERAP1 silencing, C-terminally extended peptides were readily identified. These were better able to bind to HLA–B27 than were N-terminally extended peptides lacking an arginine at position 2. In both HeLa.B27 cells and mouse fibroblasts expressing HLA–B27, the absence of ERAP1 reduced peptide recognition by HLA–B27–restricted KK10-specific CTLs following infection with recombinant vaccinia virus or transfection with minigenes expressing KK10 precursors. Presence of an AS-protective variant of ERAP1, K528R, as compared to wild-type ERAP1, reduced the peptide recognition by KK10 CTLs following transfection with extended KK10 minigenes.
Conclusion
These results show that ERAP1 directly alters peptide binding and presentation by HLA–B27, thus demonstrating a potential pathogenic mechanism in AS. Inhibition of ERAP1 could potentially be used for treatment of AS and other ERAP1-associated diseases.
This record has no associated files available for download.
More information
Accepted/In Press date: 22 October 2013
e-pub ahead of print date: 31 October 2013
Published date: February 2014
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 384904
URI: http://eprints.soton.ac.uk/id/eprint/384904
ISSN: 2326-5205
PURE UUID: 7ae391c7-ce1e-4c1a-a8a7-0705a38101a6
Catalogue record
Date deposited: 17 Dec 2015 16:58
Last modified: 15 Mar 2024 03:26
Export record
Altmetrics
Contributors
Author:
Liye Chen
Author:
Roman Fischer
Author:
Yanchun Peng
Author:
Emma Reeves
Author:
Kirsty McHugh
Author:
Nicola Ternette
Author:
Tomas Hanke
Author:
Tao Dong
Author:
Nilabh Shastri
Author:
Simon Kollnberger
Author:
Benedikt Kessler
Author:
Paul Bowness
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics